Tactile Systems Stock Price, News & Analysis

Tactile Systems Technology, Inc. (Nasdaq: TCMD) has enrolled its first patient in a significant clinical trial assessing the effectiveness of its Flexitouch^® Plus system for treating head and neck lymphedema, a condition affecting over 90% of head and neck cancer patients. This trial, the largest of its kind, aims to compare Flexitouch Plus to standard care across approximately 250 subjects at six sites. The primary outcomes will focus on swelling, symptom burden, and quality of life, evaluated over six months. This milestone highlights Tactile Medical's commitment to enhancing at-home treatment options for underserved patients.

Tactile Medical (Nasdaq: TCMD) announced the acquisition of AffloVest, a portable therapy device for chronic respiratory conditions, enhancing its position in treating underserved chronic diseases. The transaction aligns with Tactile's goal of over 20% revenue growth and gross margins above 70%. AffloVest, expected to contribute $5-5.5 million in revenue from September to December 2021, opens a $5 billion market opportunity in the U.S. The deal is financed through cash and a $55 million credit facility, with an anticipated net leverage ratio of less than 1.0 by year-end 2022.

Tactile Systems Technology, Inc. (Nasdaq: TCMD) will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference on September 9-10 and 13-15, 2021. Management's fireside chat is scheduled for September 9 at 4:15 p.m. ET. Investors can access a live audio webcast of the chat on the company’s investor relations website, with an archive available post-conference. Tactile Medical develops at-home therapy devices for chronic conditions like lymphedema, focusing on improving patient care and reducing healthcare costs.

Tactile Systems Technology, Inc. (Nasdaq: TCMD) announced its participation in the Guggenheim 2021 MedTech Disruptors Summit, taking place virtually on August 9-10, 2021. The management will engage in a fireside chat on August 9 at 3:00 p.m. Eastern Time. Tactile Medical specializes in at-home therapy devices for chronic conditions like lymphedema and chronic venous insufficiency. Their mission is to enhance patients' quality of life through advanced pneumatic compression devices and comprehensive care services, ensuring effective at-home treatment for thousands annually.

Tactile Systems Technology (Nasdaq: TCMD) reported a 45% increase in Q2 2021 revenue, totaling $51.1 million, compared to $35.1 million in Q2 2020. Net income was $1.3 million, a significant turnaround from a net loss of $13.9 million a year prior. The operating loss decreased to $0.1 million from $8.0 million. For the first half of 2021, revenue rose 19% year-over-year. The company anticipates full-year revenue between $216.3 million and $224.5 million, marking 16-20% growth. Cash and equivalents stood at $49.0 million at end of June 2021.

Tactile Systems Technology, Inc. (Nasdaq: TCMD), a medical technology company specializing in at-home treatment devices for chronic diseases, will announce its second quarter fiscal year 2021 financial results on August 2nd, after market close. A conference call hosted by management will take place at 5:00 p.m. ET the same day, with a Q&A session. Participants can join via phone or through a live webcast on the company's investor relations website. Tactile Medical focuses on home therapy devices for conditions like lymphedema and chronic venous insufficiency to improve patient care and reduce healthcare costs.

Tactile Systems Technology (Nasdaq: TCMD) announced its participation in the William Blair 41st Annual Growth Stock Conference from June 1-3, 2021. The company will host a fireside chat on June 1 at 8:40 a.m. Central Time. A live audio webcast will be available on their investor relations website, with an archive for replay post-conference. Tactile Medical specializes in at-home therapy devices for chronic conditions like lymphedema, aiming to enhance patient care and reduce healthcare costs.

Tactile Systems Technology, Inc. (TCMD) reported its Q1 2021 financial results, showing a 2% decrease in total revenue to $42.8 million year-over-year. The operating loss improved slightly to $4.1 million, while net loss increased to $2.3 million. The company maintained a cash position of $46.9 million. Despite challenges from COVID-19, management expects a recovery in Q2 and reaffirms the 2021 revenue outlook of $215.3 million to $224.5 million, indicating a potential 15%-20% growth. New appointments to the board and management aim to strengthen operations.

Tactile Medical (NASDAQ: TCMD) announced Eric Pauls as the new Senior Vice President of Sales, effective May 1, 2021, succeeding retiring Bryan Rishe. Pauls brings over 20 years of healthcare experience, having previously held senior roles at Royal Philips. His expertise includes building successful teams and expanding markets, particularly in chronic diseases like lymphedema and sleep apnea. Tactile Medical specializes in at-home therapy devices, aiming to improve patient care and reduce healthcare costs.